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Prevalence and impact of severe fatigue in adolescent and young adult 
cancer patients in comparison with population-based controls 
 
Purpose: The current study determined the prevalence of severe fatigue in Adolescent and Young Adult (AYA) 
cancer patients (aged 18-35 years at diagnosis) consulting a multidisciplinary AYA team in comparison with 
gender- and age-matched population-based controls. In addition, impact of severe fatigue on quality of life and 
correlates of fatigue severity were examined.  
Methods: AYAs with cancer (n=83) completed questionnaires including the Checklist Individual Strength (CIS-
fatigue), Quality of Life (QoL)-Cancer Survivor, Hospital Anxiety and Depression Scale (reflecting 
psychological distress), and the Cancer Worry Scale (reflecting fear of cancer recurrence or progression).  
Results: The vast majority of participants had been treated with chemotherapy (87%) and had no active 
treatment at the time of participation (73.5%). Prevalence of severe fatigue (CIS-fatigue score ≥ 35) in AYAs 
with cancer (48%, n=40/83) was significantly higher in comparison with matched population-based controls 
(20%, n=49/249; p < .001). Severely fatigued AYAs with cancer reported lower QoL compared to non-severely 
fatigued AYAs with cancer (p’s < .05). Female gender, being unemployed, higher disease stage (III-IV) at 
diagnosis, receiving active treatment at the time of study participation, being treated with palliative intent, 
having had radiotherapy, higher fear of recurrence or progression, and higher psychological distress were 
significantly correlated with fatigue severity (p’s < .05).  
Conclusions: Severe fatigue based on a validated cut-off score was highly prevalent in this group of AYAs with 
cancer. QoL is significantly affected by severe fatigue, stressing the importance of detection and management of 
this symptom in those patients affected by a life-changing diagnosis of cancer in late adolescence or young 
adulthood. 
Word count: 258  
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Introduction 
Compared to adults, a diagnosis of cancer in adolescents and young adults (AYAs) between the ages of 18 and 
35 years is rare. Advances in early detection and improvements in cancer treatments have resulted in an overall 
5-year survival rate exceeding 80% in AYAs [1]. While AYAs with cancer face challenges similar to adult 
cancer patients, those in the heart of their youth experience unique cancer-related challenges in addition to usual 
age-related developmental tasks. The combination of achieving normal developmental milestones and 
simultaneously coping with a life-changing diagnosis of cancer frequently leads to psychosocial issues among 
AYAs with cancer [2]. Several studies have documented higher levels of distress and lower quality of life (QoL) 
in AYAs with cancer in comparison with healthy matched peers or adult cancer patients [3-5]. Moreover, 
treatment-related symptoms (e.g. pain and fatigue) and late effects (e.g. second cancers and cardiovascular 
disease) can interfere with a healthy body image, establishing social relationships, or attaining levels of 
autonomy and independence. With the expected further gains in overall survival of AYA cancer, it is important 
to address persistent disease- and treatment-related symptoms that compromise several domains of QoL. 
 Cancer-related fatigue (CRF) is one of the most common and distressing symptoms reported by adult 
and childhood cancer patients both during and after cancer treatment [6, 7]. The most commonly used definition 
for CRF is formulated by the National Comprehensive Cancer Network (NCCN) and defines CRF as ‘distressing 
persistent subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or 
cancer treatment that is not proportional to recent activity that interferes with usual functioning’ [8]. The vast 
majority of studies on the prevalence and severity of CRF have been conducted in adult or childhood cancer 
patients and only a few studies evaluated fatigue severity in AYAs with cancer. Moreover, the limited AYA-
specific studies did not attempt to report on clinically relevant levels of fatigue by using a validated cut-off for 
severe fatigue [4, 9].  
Knowledge on the prevalence of severe fatigue in AYAs with cancer is important, as we know from 
studies in adult cancer patients that severe fatigue is associated with more functional impairments, lower QoL, 
and more distress [6, 10]. For AYAs with cancer, the impact of severe fatigue might be even more pronounced 
because it can interrupt developmental milestones such as completing education, finding first or pursuing 
employment, beginning a romantic relationship, or starting a family. Understanding factors related to severe 
fatigue among AYAs with cancer will help health care providers identify who is more likely to experience this 
symptom. In addition, it will help researchers to determine potential factors that could be addressed in 
interventions targeting fatigue.  
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 The present study determined the prevalence of clinically relevant levels of fatigue in AYAs with 
cancer using a validated cut-off for severe fatigue and compared the proportion of severely fatigued cases with 
the proportion of severely fatigued cases in a sample of gender- and age-matched population-based controls. In 
addition, the impact of severe fatigue on QoL and potential sociodemographic, treatment-related, and 
psychological correlates of fatigue severity was explored. A cross-sectional approach was used for this study to 
gather descriptive information about the presence of clinically relevant levels of fatigue among AYAs with 
cancer.  
 
Materials and Methods 
Patients 
Patients aged 18-35 years at cancer diagnosis and who had been seen by at least one of the members of the AYA 
team of the Radboud university medical center, Nijmegen, The Netherlands, were invited to participate in this 
study. The AYA team is a dedicated multidisciplinary team including a medical oncologist, clinical nurse 
specialist, medical psychologist, and social worker. Patients consulting the AYA team receive regular medical 
care from their own treating specialist (oncologist, surgeon, haematologist, dermatologist, urologist, 
gynaecologist, etc.) and visit the AYA team for age-specific questions and care needs. In general, patients 
visiting the AYA team represent a group of patients with higher disease severity, diagnosed with relatively 
advanced stage of disease and undergoing intensive treatments, and reporting more problems with coping. The 
AYA team does not often see patients with low stage disease treated solely by surgery, such as in the case of thin 
melanomas.  
To depict the real-life heterogeneous sample of AYAs with cancer visiting the AYA team, AYAs with 
cancer were included in this first study on the prevalence of severe fatigue regardless of treatment status (during 
or after treatment), type of treatment (surgery, chemotherapy, radiotherapy, immunotherapy, hormonal therapy 
or combination), or the number of AYA team visits (some patients only had one introduction talk with one of the 
members of the team and did not receive specific care thereafter). Inclusion commenced January 2012 and ended 
March 2016.  
 
Population-based controls 
Population-based controls were derived from a cohort of panel members surveyed by CentERdata, a research 
institute at Tilburg University collecting data from a sample of more than 2000 Dutch households 
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(https://www.centerdata.nl/en/). This CentERpanel represents the adult Dutch-speaking population with respect 
to demographic characteristics. Population-based controls provided self-reported data on age and gender and 
completed a multi-dimensional fatigue questionnaire (Checklist Individual Strength, see measures). They had no 
sickness absence in the workplace (0 days) in the month prior to filling in the questionnaires. Further information 
on the presence of physical or mental health conditions in population-based controls was not available. 
 
Procedure 
Potential study participants were recruited via letters describing the study and inviting patients to participate in 
the study. Patients willing to participate had to actively opt-in to the study by providing written informed consent 
by email to a member of the AYA team. Participants were then sent a single set of questionnaires by email that 
could be completed online. The study was deemed exempt from full review and approval by a research ethics 
committee (CMO Regio Arnhem-Nijmegen, #2016-2872). 
 
Measures 
AYAs with cancer completed a self-report questionnaire on sociodemographic data (i.e., age, gender, partner 
status, having children, education level, and employment status). A member of the AYA team (S.K.) extracted 
clinical data (i.e., cancer diagnosis, disease stage at diagnosis, time since initial cancer diagnosis, type(s) of 
treatment(s) received, duration of cancer treatment, treatment status at participation, and time since completion 
of cancer treatment) from patients’ medical records. AYAs with cancer completed the following questionnaires, 
including a multi-dimensional fatigue questionnaire: 
Checklist Individual Strength, subscale fatigue severity (CIS-fatigue). The subscale fatigue severity of 
the CIS consists of eight items scored on a 7-point Likert scale. Total CIS-fatigue scores can range from 8 to 56, 
with scores greater than 34 indicating clinically relevant levels of fatigue [11]. The CIS-fatigue has been used in 
previous studies examining severe fatigue in cancer patients during and after cancer treatment [12-14]. A cut-off 
was used to group AYAs with cancer into two groups to indicate severely fatigued (≥ 35) and non-severely 
fatigued patients (< 35).  
Quality of Life-Cancer Survivor (QoL-CS). The QoL-CS consists of 41 items scored on a 10-point 
Likert scale and was used as a cancer-specific measure of QoL [15]. The impact of cancer diagnosis and 
treatment is assessed with four subscales, i.e., physical, social, psychological, and spiritual wellbeing. In addition 
to the four subscale scores, the total QoL score reflecting the average across all items was used in this study. 
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Higher scores indicated better QoL for all subscales.  
Hospital Anxiety and Depression Scale (HADS). The HADS consists of 14 items scored on a 4-point 
Likert scale [16]. The summed total HADS scores range from 0 to 42, and were used to reflect psychological 
distress in our sample of AYAs with cancer [17]. Higher total scores indicate more psychological distress. 
Cancer Worry Scale (CWS). The CWS consists of eight items regarding concerns about cancer 
recurrence or progression of cancer. Items are scored on a 4-point Likert scale ranging from ‘never’ to ‘almost 
always’ [18]. Total CWS scores range from 8 to 32, and can be used to assess cancer worrying. Higher total 
scores indicate more fear of cancer recurrence or progression. Patients with a recent recurrence (n = 5) or 
receiving treatment with palliative intent (n = 7) did not complete the CWS because the item wording of this 
measure was irrelevant to them. 
 
Statistical Analyses 
To compare mean fatigue severity and the prevalence of severe fatigue in AYAs with cancer with population-
based controls derived from the sample of CentERdata (n = 1923), AYAs with cancer were matched on gender 
and age (within a range of 0 to 5 years) with 249 population-based controls. Given the relatively low proportion 
of CentERpanel members within the age range of our study sample, the highest possible ratio for matching 
AYAs with cancer to controls was 1:3. Precision matching was performed with STATA/SE. All other analyses 
were performed using SPSS Statistics (version 22.0). Descriptive statistics and frequencies concerning socio-
demographic and clinical data were calculated. An independent samples t-test was used to compare fatigue 
severity scores between AYAs with cancer and matched population-based controls. We used a Chi-square test to 
compare the proportion of severely fatigued cases in AYAs with cancer and matched population-based controls. 
Pearson and Point-Biserial correlations were calculated to examine associations between continuous variables or 
continuous and dichotomous variables, respectively. The significance level was set at .05. We did not adjust for 
multiple testing. 
 
Results 
In total, 309 letters requesting participation in the study were sent to AYAs with cancer visiting one of the 
members of the AYA team. The total sample of 89 participants comprised 57% of those who opted-in to the 
study (n = 155) and 29% of all those solicited by mail (n = 309). Six participants were excluded, four since they 
were diagnosed with cancer under the age of 18 years and two because they were aged above 35 years at 
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diagnosis. Table 1 displays sociodemographic, disease and treatment-related characteristics of the final sample 
of 83 AYAs with cancer stratified by the presence of severe fatigue. Mean age at cancer diagnosis for the total 
sample was 27.3 years (SD 4.4) and mean time since cancer diagnosis was 2.1 years (SD 2.6). The most 
common diagnosis was testicular cancer (34%) followed by sarcoma (19%). Disease stage at diagnosis was 
known and applicable in 67 participants. Of those, 36 (54%) were diagnosed with early-stage disease (stages I-
II) and 31 (46%) with late-stage disease (stages III-IV). The majority of participants had undergone surgery (n = 
70, 84%) and chemotherapy (n = 72, 87%), but were not on active cancer treatment at the time of study 
participation (n = 61, 73.5%). Mean duration of cancer treatment was 15.8 months (SD 20.6). For the subset of 
61 patients not on active cancer treatment at the time of study participation, mean duration since completion of 
treatment was 17.5 months (SD 30.6). 
 
Prevalence of Severe Fatigue and Impact on Quality of Life 
AYAs with cancer reported a significantly higher fatigue severity score than matched population-based controls 
(31.5, SD 11.8 versus 24.9, SD 10.5, respectively, p < .001). The prevalence of severe fatigue in AYAs with 
cancer was significantly higher in comparison with matched population-based controls (48%, n = 40/83 versus 
20%, n = 49/249, respectively, p < .001). Severely fatigued AYAs with cancer reported significantly lower 
scores on all four QoL subscales (i.e., physical, social, psychological, and spiritual well-being) and on total QoL, 
compared to their non-severely fatigued counterparts (p’s < .05, see Table 2). 
 
Sociodemographic, Treatment-Related, and Psychosocial Correlates of Fatigue Severity 
Correlations are listed in Table 3. Higher psychological distress was strongly correlated to fatigue severity (R = 
.55; p < .001).  Female gender, being unemployed (not having a job, sick leave or disablement insurance act), 
higher disease stage (III-IV) at diagnosis, and higher fear of recurrence or progression were moderate correlates 
(R‘s 0.30 to 0.50; p’s < .01). In addition, receiving active treatment at the time of study participation, palliative 
intent of treatment, and having had radiotherapy were weakly associated with fatigue severity (R‘s 0.10 to 0.30; 
p’s < .05). No significant associations were observed between fatigue severity and the other sociodemographic, 
disease- and treatment related variables (see Table 3; p’s > .05). 
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Discussion 
In this study, severe fatigue affected almost half of the AYAs with cancer. The prevalence of severe fatigue in 
AYAs with cancer was more than twice as high in AYAs with cancer than in gender- and age-matched 
population-based controls (48% versus 20%). Severe fatigue as assessed with the CIS-fatigue is more prevalent 
amongst AYAs with cancer than adult disease-free breast cancer patients 3 years after diagnosis (38%) [19]. The 
prevalence amongst AYAs with cancer corresponds more closely with findings from a study performed in adult 
cancer patients during cancer treatment with palliative intent (47%) [13], which is remarkable given the major 
difference in prognosis between these two patient groups. In our sample, only a minority of the participants (n = 
12, 14.5%) were classified as being treated with palliative intent at the time of participation. Reasons for the high 
prevalence of severe fatigue in AYAs with cancer have not been studied. One might postulate that, in contrast to 
adult cancer patients, the higher prevalence of severe fatigue originates from the unique combination of being 
diagnosed and treated for cancer and the developmental milestones AYAs are confronted with during 
adolescence and young adulthood. 
Alternatively, the higher prevalence of severe fatigue reported by participants in our study could be the 
result of selection bias. We recruited AYAs with cancer that consulted a multidisciplinary AYA team. The fact 
that patients consulted a specialized AYA team most likely indicates that these patients had additional disease 
and/or treatment-related questions or problems, although not all patients had a need for continued and specific 
care by the AYA team after the first consultation. The percentage of patients having had chemotherapy as part of 
AYA cancer treatment was high (87%). This further supports the likelihood of selection bias in our sample and 
might overestimate disease severity of the entire AYA cancer patient population. Nonetheless, we can conclude 
that within the subset of AYAs with cancer consulting a multidisciplinary AYA team, the prevalence of severe 
fatigue is substantial.  
Significant differences were found in physical, social, psychological, spiritual, and total QoL for 
severely fatigued AYAs with cancer in comparison with non-severely fatigued patients, which echoes previous 
studies reporting on the detrimental effects of severe fatigue in adult cancer patients [6, 10]. More psychological 
distress was a strong correlate of fatigue severity in the present study. In addition, more cancer worrying, female 
gender, and being unemployed were moderately related to fatigue severity. Geue et al. (2014) studied gender-
specific differences in quality of life after AYA cancer and found lower QoL for women than men, including 
higher levels of fatigue [20]. The finding that more psychological distress and cancer worrying were associated 
with fatigue severity is in agreement with the impact of fatigue severity on QoL of AYAs with cancer in this 
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study. However, given the cross-sectional design of our study we cannot draw conclusions on causality. This 
also limits interpreting the finding that being unemployed was linked to higher fatigue severity, although it may 
suggest that severely fatigued AYAs with cancer might not be able to find appropriate work. This emphasises the 
relevance of further research into this topic. 
We only found weak or non-significant links between treatment-related variables and fatigue severity; 
receiving active treatment at the time of study participation, receiving treatment with palliative intent, and 
having had radiotherapy were significant but weakly related to fatigue severity. A moderate association was 
found between late-stage cancer at diagnosis and fatigue severity. In previous studies among adult cancer 
patients during and after treatment, fatigue appeared to be unrelated to disease-related variables, but the receipt 
of chemotherapy was associated with fatigue long after treatment [21]. A recently published review among 
breast cancer survivors after treatment also reported that survivors treated with chemotherapy were at higher risk 
for developing severe fatigue, as were those survivors with a higher disease stage at diagnosis [22]. As 
mentioned before, a noteworthy proportion of participants (87%) in our sample had been treated with 
chemotherapy. 
The present study has several limitations. The sample size of our study was relatively small and the low 
participation rate increases the probability of bias by non-response. Unfortunately, small sample sizes are also 
seen in other studies in which patients of AYA age are asked to participate [23, 24]. Recruitment for our study 
took place over a period of 4 years. Additional efforts to increase data collection, such as multiple mailings of 
questionnaires or follow-up phone calls, were only made in the latter part of the study. Our response rate might 
have been higher when these efforts were made throughout the entire duration of the study. However, in the 
AYA HOPE study fewer than half of the eligible AYAs with cancer responded to questionnaires despite 
extensive efforts such as multiple mailings, phone calls, and financial incentives [25]. One way to overcome the 
low response rate in AYA cancer research might be the use of in-person contact and patient-preferred paper-
pencil rather than online surveys as recently suggested by Rosenberg et al. [26]. Given the low incidence of 
cancer in AYAs between the ages of 18 to 35 years, recruitment from multiple institutions in an (inter)national 
AYA network could also aid the collection of larger samples. This would also increase the ability to generalize 
findings, which is limited in our study since we recruited patients at a single university medical center. While a 
broad range of potential correlates of fatigue severity was studied, we cannot rule out the involvement of other 
potentially relevant factors that have not been examined in this study. For example, sleep problems are strongly 
correlated with higher levels of fatigue in patients with cancer [27]. In addition, a low level of physical activity 
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and pain are also correlated with cancer-related fatigue [28]. There is evidence that the effect of sleep problems 
on fatigue is mediated by pain [29]. Unfortunately, we did not include validated instruments to assess sleep 
problems, physical activity, and pain as potential correlates of fatigue severity in our sample, which is a 
significant limitation of the study. Notwithstanding these limitations, the present study is the first to apply a 
clinically relevant cut-off for severe fatigue in AYAs with cancer aged between 18 and 35 years at diagnosis. 
In conclusion, given the high prevalence and significant impact of severe fatigue on quality of life of 
AYAs with cancer, health care providers should pay careful attention to this symptom. In particular, female 
AYAs with cancer, those with more advanced disease at diagnosis, higher levels of psychological distress, and 
more cancer worrying seem to experience higher levels of fatigue. The longer-term survivorship rates of AYA 
cancer illustrate the potential longevity of AYAs with cancer. It is therefore important to investigate the course 
and persistence of severe fatigue in AYAs with cancer in longitudinal, population-based studies. Such studies 
would also aid the development of age-specific interventions addressing persistent cancer-related fatigue in 
AYAs with cancer to enable full participation in society throughout survivorship. Although evidence-based 
interventions for the management of cancer-related fatigue in adult cancer survivors are available and 
recommended within guidelines issued by the American Society for Clinical Oncology [30], these interventions 
have not been tested extensively in AYAs with cancer. Researchers should investigate whether these 
interventions can also be successfully applied to alleviate persistent cancer-related fatigue, improve QoL, and 
facilitate participation in society for the understudied population of AYAs with cancer. 
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Table 1. Characteristics of the study sample stratified by fatigue severity 
Characteristics Total 
sample 
(n = 83) 
Non-severely 
fatigued patients  
(n = 43) 
Severely fatigued  
patients  
(n = 40) 
Age at cancer diagnosis, mean 
(SD) 
18-25 years 
26-35 years 
 
27.3 (4.4) 
30 (36%) 
53 (64%) 
 
26.5 (4.6) 
18 (42%) 
25 (58%) 
 
28.0 (4.1) 
12 (30%) 
28 (70%) 
Age at participation, mean (SD) 
18-25 years 
26-35 years 
> 35 years 
29.4 (4.7) 
19 (23%) 
58 (70%) 
6 (7%) 
28.7 (5.0) 
13 (30%) 
27 (63%) 
3 (7%) 
30.2 (4.4) 
6 (15%) 
31 (77.5%) 
3 (7.5%) 
Gender 
Male 
Female 
 
43 (52%) 
40 (48%) 
 
30 (70%) 
13 (30%) 
 
13 (32.5%) 
27 (67.5%) 
Partner a 
Yes 
No 
 
58 (70%) 
24 (29%) 
 
32 (74%) 
11 (26%) 
 
26 (67%) 
13 (33%) 
Children a 
Yes 
No 
 
27 (33%) 
55 (66%) 
 
30 (70%) 
13 (30%) 
 
25 (64%) 
14 (36%) 
Highest completed education a 
Low 
Intermediate 
High 
 
2 (2%) 
36 (43%) 
44 (53%) 
 
0 (0%) 
18 (42%) 
25 (58%) 
 
2 (5%) 
18 (46%) 
19 (49%) 
Employed or studying a 
Yes 
No 
Other 
 
53 (64%) 
26 (31%) 
3 (4%) 
 
37 (86%) 
4 (9%) 
2 (5%) 
 
16 (40%) 
22 (55%) 
1 (2.5%) 
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Table 1. Characteristics of the study sample stratified by fatigue severity (continued) 
Characteristics Total sample 
(n = 83) 
Non-severely fatigued 
patients (n = 43) 
Severely fatigued  
patients (n = 40) 
Cancer diagnosis 
Testicular cancer 
Sarcoma  
Breast cancer 
Hematological malignancy 
Gynecological cancer 
Melanoma 
Other b 
 
28 (34%) 
16 (19%) 
10 (12%) 
10 (12%) 
9 (11%) 
3 (4%) 
7 (8%) 
 
22 (51%) 
5 (12%) 
4 (9%) 
2 (5%) 
5 (12%) 
2 (5%) 
3 (7%) 
 
6 (15%) 
11 (27.5%) 
6 (15%) 
8 (20%) 
4 (10%) 
1 (2.5%) 
4 (10%) 
Cancer stage at diagnosis 
Not applicable 
Stage I 
Stage II 
Stage III 
Stage IV 
Unknown 
 
9 (11%) 
11 (13%) 
25 (30%) 
13 (16%) 
18 (22%) 
7 (8%) 
 
3 (7%) 
6 (14%) 
18 (42%) 
3 (7%) 
11 (26%) 
2 (5%) 
 
6 (15%) 
5 (12.5%) 
7 (17.5%) 
10 (25%) 
7 (17.5%) 
5 (12.5%) 
Time since cancer diagnosis,  
mean (SD) in years 
 
2.1 (2.6) 
 
2.0 (1.8) 
 
2.2 (3.3) 
Lifetime cancer treatment c  
Surgery 
Chemotherapy 
Radiotherapy 
Immuno- or targeted therapy 
Hormone therapy 
 
70 (84%) 
72 (87%) 
24 (29%) 
13 (16%) 
7 (8%) 
 
38 (88%) 
38 (88%) 
10 (23%) 
5 (12%) 
4 (9%) 
 
32 (80%) 
34 (85%) 
14 (35%) 
8 (20%) 
3 (7.5%) 
Intent of cancer treatment 
Curative 
Palliative 
 
71 (85.5%) 
12 (14.5%) 
 
40 (93%) 
3 (7%) 
 
31 (77.5%) 
9 (22.5%) 
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Table 1. Characteristics of the study sample stratified by fatigue severity (continued) 
Characteristics Total sample 
(n = 83) 
Non-severely fatigued 
patients (n = 43) 
Severely fatigued  
patients (n = 40) 
Duration of cancer treatment, 
mean (SD) in months 
 
15.8 (20.6) 
 
15.0 (22.1) 
 
16.7 (19.2) 
Treatment status at 
participation 
No active treatment  
Active treatment 
 
 
61 (73.5%) 
22 (26.5%) 
 
 
36 (83.7%) 
7 (16.3%) 
 
 
25 (62.5%) 
15 (37.5%) 
a Information was not available for n = 1 AYA with cancer. b Including: glioma (n = 1) sigmoid carcinoma (n = 
1), oropharyngeal cancer (n = 1), neuroendocrine tumor (n = 1), lung cancer (n = 1), salivary gland cancer (n = 
1), and adrenal cancer (n = 1).c Multiple answers possible.  
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Table 2. Impact of Severe Fatigue on Quality of Life of AYAs with cancer 
 Non-severely 
fatigued AYAs 
with cancer 
(n = 43) 
Severely fatigued 
AYAs with 
cancer 
(n = 40) 
  
 
QoL-CS 
 
Mean (SD) 
 
Mean (SD) 
Mean 
difference 
 
Sig. 
Physical well-being 
Social well-being 
Psychological well-being 
Spiritual well-being 
Total QoL 
8.28 (1.21) 
5.41 (1.33) 
6.27 (1.29) 
4.21 (1.16) 
6.12 (0.82) 
6.57 (1.49) 
4.81 (1.30) 
4.90 (1.59) 
3.29 (1.36) 
4.95 (1.13) 
-1.71 
-0.60 
-1.37 
-0.92 
-1.17 
.000** 
.042* 
.000** 
.001** 
.000** 
*Mean difference is significant at the 0.05 level. **Mean difference is significant at the 0.01 level. 
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Table 3. Correlates of Fatigue Severity in AYAs with cancer 
 Correlation 
coefficients 
 
No. 
 
Sig. 
Sociodemographic variables 
Age at cancer diagnosis 
Age at participation 
Gender (male/female) 
Partner status (yes/no) 
Children (yes/no) 
Employed or studying (yes/no) 
 
.194 
.185 
.336 
.118 
-.122 
.394 
 
83 
83 
83 
82 
82 
79 
 
.079 
.093 
.002** 
.291 
.273 
.000** 
Disease and treatment-related variables 
Time since cancer diagnosis 
Cancer stage at diagnosis (early/late)a 
Duration of cancer treatment 
Cancer treatment at participation (yes/no) 
Time since completion of cancer treatment 
Intent of cancer treatment (curative/palliative)  
Surgery (yes/no) 
Chemotherapy (yes/no) 
Radiotherapy (yes/no) 
Immuno- or targeted therapy (yes/no) 
Hormone therapy (yes/no) 
 
.073 
.322 
.087 
-.227 
.060 
.270 
.178 
.115 
-.242 
-.107 
.064 
 
83 
67  
81 
83 
61 
83 
83 
83 
83 
83 
83 
 
.513 
.008* 
.439 
.039* 
.646 
.013* 
.108 
.302 
.028* 
.336 
.563 
Psychological variables 
Psychological distress (HADS total) 
Fear of recurrence or progression (CWS total)b 
 
.553 
.340 
 
83 
71  
 
.000** 
.004** 
*Correlation is significant at the 0.05 level. **Correlation is significant at the 0.01 level.  
a
 Cancer stage was unknown for n = 7 AYAs with cancer and not applicable for n = 9 AYAs with cancer. b CWS 
was not administered to n = 12 AYAs with cancer, because they either had a recurrence (n = 5) or received 
treatment with palliative intent (n = 7). 
 
